Literature DB >> 11733373

Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon.

T Hinoi1, M Tani, P C Lucas, K Caca, R L Dunn, E Macri, M Loda, H D Appelman, K R Cho, E R Fearon.   

Abstract

Most large bowel cancers are moderately to well-differentiated adenocarcinomas comprised chiefly or entirely of glands lined by tall columnar cells. We have identified a subset of poorly differentiated colon carcinomas with a distinctive histopathological appearance that we term large cell minimally differentiated carcinomas (LCMDCs). These tumors likely include a group of poorly differentiated carcinomas previously described by others as medullary adenocarcinomas. To better understand the pathogenesis of these uncommon neoplasms, we compared molecular features of 15 LCMDCs to those present in 25 differentiated adenocarcinomas (DACs) of the colon. Tumors were examined for alterations commonly seen in typical colorectal carcinomas, including increased p53 and beta-catenin immunoreactivity, K-ras gene mutations, microsatellite instability, and loss of heterozygosity of markers on chromosomes 5q, 17p, and 18q. In addition, tumors were evaluated by immunohistochemistry for CDX2, a homeobox protein whose expression in normal adult tissues is restricted to intestinal and colonic epithelium. Markedly reduced or absent CDX2 expression was noted in 13 of 15 (87%) LCMDCs, whereas only 1 of the 25 (4%) DACs showed reduced CDX2 expression (P < 0.001). Nine of 15 (60%) LCMDCs had the high-frequency microsatellite instability phenotype, but only 2 of 25 (8%) DACs had the high-frequency microsatellite instability phenotype (P = 0.002). Our findings provide support for the hypothesis that the molecular pathogenesis of LCMDCs is distinct from that of most DACs. CDX2 alterations and DNA mismatch repair defects have particularly prominent roles in the development of LCMDCs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733373      PMCID: PMC1850596          DOI: 10.1016/S0002-9440(10)63074-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Improved prognosis of solid-type poorly differentiated colorectal adenocarcinoma: a clinicopathological and immunohistochemical study.

Authors:  Y Sugao; T Yao; C Kubo; M Tsuneyoshi
Journal:  Histopathology       Date:  1997-08       Impact factor: 5.087

2.  Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics.

Authors:  J Rüschoff; W Dietmaier; J Lüttges; G Seitz; T Bocker; H Zirngibl; J Schlegel; H K Schackert; K W Jauch; F Hofstaedter
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Anaplastic carcinoma of the colon: clinicopathologic study of eight cases of a poorly recognized lesion.

Authors:  C V Reyes; M T Siddiqui
Journal:  Ann Diagn Pathol       Date:  1997-10       Impact factor: 2.090

4.  High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability.

Authors:  R Dolcetti; A Viel; C Doglioni; A Russo; M Guidoboni; E Capozzi; N Vecchiato; E Macrì; M Fornasarig; M Boiocchi
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

5.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.

Authors:  A B Sparks; P J Morin; B Vogelstein; K W Kinzler
Journal:  Cancer Res       Date:  1998-03-15       Impact factor: 12.701

6.  Molecular characteristics of poorly differentiated adenocarcinoma and signet-ring-cell carcinoma of colorectum.

Authors:  Y Kawabata; N Tomita; T Monden; M Ohue; T Ohnishi; M Sasaki; M Sekimoto; I Sakita; Y Tamaki; J Takahashi; T Yagyu; H Mishima; N Kikkawa; M Monden
Journal:  Int J Cancer       Date:  1999-02-19       Impact factor: 7.396

Review 7.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

8.  CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer.

Authors:  C Wicking; L A Simms; T Evans; M Walsh; K Chawengsaksophak; F Beck; G Chenevix-Trench; J Young; J Jass; B Leggett; B Wainwright
Journal:  Oncogene       Date:  1998-08-06       Impact factor: 9.867

9.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma.

Authors:  J G Herman; A Umar; K Polyak; J R Graff; N Ahuja; J P Issa; S Markowitz; J K Willson; S R Hamilton; K W Kinzler; M F Kane; R D Kolodner; B Vogelstein; T A Kunkel; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

10.  Genomic structure and alterations of homeobox gene CDX2 in colorectal carcinomas.

Authors:  O K Yagi; Y Akiyama; Y Yuasa
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  57 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

2.  Hierarchical clustering identifies a subgroup of colonic adenocarcinomas expressing crypt-like differentiation markers, associated with MSS status and better prognosis.

Authors:  Laure Droy-Dupré; Céline Bossard; Christelle Volteau; Stéphane Bezieau; Christian L Laboisse; Jean-François Mosnier
Journal:  Virchows Arch       Date:  2015-02-11       Impact factor: 4.064

3.  Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.

Authors:  Jeong Mo Bae; Tae Hun Lee; Nam-Yun Cho; Tae-You Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

4.  The microenvironment controls CDX2 homeobox gene expression in colorectal cancer cells.

Authors:  Fairouz Benahmed; Isabelle Gross; Dominique Guenot; Frédéric Jehan; Elisabeth Martin; Claire Domon-Dell; Thomas Brabletz; Michèle Kedinger; Jean-Noël Freund; Isabelle Duluc
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

5.  No association between the polymorphisms in CDX2 coding regions and colorectal cancer in Chinese.

Authors:  Xiaoping Xia; Enping Xu; Sheng Quan; Qiong Huang; Maode Lai
Journal:  Mol Cell Biochem       Date:  2009-05-07       Impact factor: 3.396

Review 6.  Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

Authors:  Jung Ho Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

7.  The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development.

Authors:  C Bonhomme; I Duluc; E Martin; K Chawengsaksophak; M-P Chenard; M Kedinger; F Beck; J-N Freund; C Domon-Dell
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 8.  Poorly differentiated medullary carcinoma of the colon with an unusual phenotypic profile mimicking high grade large cell lymphoma - a unique case report and review of the literature.

Authors:  Johnny Nguyen; Domenico Coppola; Yuan Shan; Ling Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

9.  Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.

Authors:  Brody Winn; Rosemarie Tavares; Jacqueline Fanion; Lelia Noble; John Gao; Edmond Sabo; Murray B Resnick
Journal:  Hum Pathol       Date:  2008-11-07       Impact factor: 3.466

10.  Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2.

Authors:  Michael Koslowski; Ozlem Türeci; Christoph Huber; Ugur Sahin
Journal:  Mol Cancer       Date:  2009-09-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.